Skip to main content
. 2015 Aug 17;35(6):558–565. doi: 10.1007/s10875-015-0190-0

Fig. 3.

Fig. 3

(A-D): Length percentile measurements are shown at the start and completion of Hizentra® therapy for 74 patients. A and B include females (<=24 and >24–59 months, respectively). C and D similarly show males (<=24 and >24–59 months, respectively). Each line represents 1 patient, and red diamonds (Inline graphic) represent mean length percentile at first and last measurement on Hizentra®